Your trusted source for investing success
The Canadian Securities Exchange launched a new index meant to account for the largest companies on the exchange, some of the top weighing companies in the index operate in the cannabis business.
The biotech sector has steadily enjoyed an increase this year, in part thanks to significant advancements and in spite of the uncertainty from the White House as the proposal of a new healthcare bill holds the grip of most life science markets.
The Investing News Network (INN) takes a closer look at the top biotech companies listed on the NASDAQ so far this year, with a market cap between 50 and 500 million.
CASI Pharmaceuticals, Savara, Adverum Biotechnologies, ChromaDex Therapeutics and MannKind top the NASDAQ biotech stock list.
eGain Corporation, Internet Gold-Golden Lines, Planet Payment, RealNetworks and ModusLink Global Solutions were last week’s top gainers.
The Investing News rounds some of the biggest news in the cannabis market for the past trading week
The global stem cell therapy market is expected to grow at a CAGR of 36.52 percent between 2017 and 2021. Here are 10 top stem cell companies on the NASDAQ.
The medical device industry is robust and diverse. Here are four small medical device companies that investors should watch.
Major players in the pharmaceutical industry include Johnson & Johnson, Novartis, Roche, Pfizer and Merck.
By Jocelyn Aspa
The Canadian marijuana sector is one of the hottest growing sectors. Here’s a look at Canadian cannabis companies for investors to consider.
Neovasc, Adaptimmune, Curis, Vericel and MannKind top the NASDAQ biotech stock list.
The Investing News reported took a closer look at some of the big cannabis news of the week and published an interview with the president of Cannabis Wheaton.
Theralase Technologies released their financial report for the second quarter of 2017.
BioVie reported its financial report for the fiscal year 2017 and provided shareholders with a clinical development progress.
Cardiome saw significant decreases on both its stocks as a reaction to the decision from the FDA.
Delcath Systems, MannKind, Zogenix, BioLife Solutions and BioDelivery Sciences top the NASDAQ biotech stock list.
BioCorRx released their financial report for the second quarter of 2017 and provided a business update to shareholders.
Ophthotech announced it failed to meet its endpoint of mean change in visual acuity at the 12-month mark for a Phase 3 clinical trial of Fovista compared to Eyla or Avastin.
MedReleaf released its financial report for the first quarter of 2017.
Moleculin Biotech released their financial report for the second quarter of 2017.
